3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

Inclusion Criteria: * Histological confirmed advanced well differentiated typical and atypical carcinoid tumors of the lung or thymus * Patients of all treatment lines including naive patients could have been enrolled * At least one measurable lesion of disease on CT scan or MRI * Radiological documentation of disease progression within 12 months prior to randomization * Adequate liver, renal and bone marrow function * WHO Performance Status 0-2 Exclusion Criteria: * Poorly differentiated neuroendocrine carcinoma * Non-neuroendocrine thymoma * Patients with severe functional disease who required symptomatic treatment with somatostatin analogs * Prior therapy with mTOR inhibitors * History of liver disease * Baseline QTcF\> 470 msec * Uncontrolled diabetes mellitus despite adequate therapy